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Hepatitis C virus (HCV) remains a major medical problem. In-depth study of HCV pathogenesis and
immune responses is hampered by the lack of suitable small animal models. The narrow host range of
HCV remains incompletely understood. We demonstrate that the entire HCV life-cycle can be
recapitulated in mouse cells. We show that antiviral signaling interferes with HCV RNA replication in
mouse cells. We were able to infect mouse cells expressing human CD81 and occludin (OCLN)—the
minimal set of entry factor factors required for HCV uptake into mouse cells. Infected mouse cells sustain
HCV RNA replication in the presence of miR122 and release infectious particles when mouse apoE is
supplied. Our data demonstrate that the barriers of HCV interspecies transmission can be overcome by
engineering a suitable cellular environment and provide a blue-print towards constructing a small
animal model for HCV infection.
& 2013 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV), the causative agent of classically
deﬁned non-A, non-B hepatitis, is highly prevalent, with approxi-
mately 3% of the worldwide population infected. Acute HCV
infection often evades immune-mediated clearance and results
in chronic, life-long persistence. Chronic infections can have
severe health consequences, including hepatitis, cirrhosis, liver
failure, and hepatocellular carcinoma. Treatment options are
limited and are often plagued with serious side effects. A pre-
ventative or therapeutic vaccine for HCV does not exist.
HCV has been notoriously difﬁcult to study in cell culture and
in vivo systems (reviewed in Dustin and Rice (2007)), which has
hampered development of more tolerable and effective therapies.
Few species are known to be susceptible to HCV infection,ll rights reserved.
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ny.including humans, chimpanzees and tree shrews (reviewed in
Bukh (2012)). The HCV life cycle is blocked or insufﬁciently
supported at multiple steps in murine cells and the barriers for
interspecies transmission remain poorly deﬁned (reviewed in
Sandmann and Ploss (2013)). To enter hepatocytes, HCV utilizes
several host proteins including glycosaminoglycans (GAGs) (Barth
et al., 2003; Koutsoudakis et al., 2006), the low density lipoprotein
receptor (LDLR) (Agnello et al., 1999; Molina et al., 2007;
Monazahian et al., 1999; Owen et al., 2009), the high density
lipoprotein receptor scavenger receptor class B type I (SCARB1;
Scarselli et al., 2002), tetraspanin CD81 (Pileri et al., 1998), and two
tight junction (TJ) proteins, claudin-1 (CLDN1; Evans et al., 2007)
and occludin (OCLN; Liu et al., 2009; Ploss et al., 2009). CD81,
SCARB1, CLDN1 and OCLN comprise the minimal set of host factors
required for HCV uptake into mouse cell lines, where only CD81
and OCLN must be of human origin to overcome the species
barrier in mouse cell lines (Ploss et al., 2009) and genetically
humanized mice (Dorner et al., 2011). More recently, additional
host factors including the cholesterol absorption receptor Niemann–
Pick C1-like 1 (NPC1L1; Sainz et al., 2012) and two receptor
tyrosine kinases, epidermal growth factor receptor (EGFR;
Lupberger et al., 2011) and EphrinA2 (Lupberger et al., 2011) have
been implicated in the viral uptake pathway into human cells.
Mouse and human EGFR and EphrinA2 both share approximately
A. Vogt et al. / Virology 444 (2013) 1–11290% amino acid sequence identity, suggesting that functionality
within the HCV entry pathway maybe conserved across species.
Interestingly, NPC1L1 is not expressed in the mouse liver (Altmann
et al., 2004). Nonetheless, it was demonstrated that mice expres-
sing human CD81 and OCLN support HCV uptake into mouse
hepatocytes (Dorner et al., 2011) suggesting that lack of NPC1L1
does not limit HCV infection of murine cells.
Following uptake into murine cells, HCV RNA is translated
(Dorner et al., 2011; McCaffrey et al., 2002) but does not appear to
accumulate, suggesting that viral RNA replication is impaired in
mouse cells. HCV RNA replicons, which are selectable HCV RNA
genomes, can replicate in murine cell lines (Frentzen et al., 2011;
Uprichard et al., 2006; Zhu et al., 2003), demonstrating that
interfering dominant negative inhibitors do not appear to exist.
These observations also suggest that murine orthologs of host
factors critical for HCV replication appear to cooperate sufﬁciently
with the viral replication machinery.
Several reports have hinted that antiviral cellular defenses limit
HCV genome propagation. For example, both human hepatoma
cells (Blight et al., 2002; Sumpter et al., 2005) as well as human
primary hepatocytes impaired in innate immunity are more
conducive to viral replication (Andrus et al., 2011; Marukian
et al., 2011). It was reported that HCV can counteract innate
immune defenses in human cells, e.g. by cleavage of the mito-
chondrial antiviral signal protein (MAVS) (Meylan et al., 2005) or
Toll/IL-1 receptor domain-containing adapter inducing IFN-beta
(TRIF or TICAM; Li et al., 2005). However, these mechanisms may
not work with equal efﬁciency in all cell types and species. In fact,
it was recently shown that MAVS from multiple primates is
resistant to inhibition by the HCV NS3/4A protease (Patel et al.,
2012). This resistance maps to single amino acid changes within
the protease cleavage site in MAVS, which protect MAVSNS3/4A mock
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Fig. 1. The HCV NS3/4A serine protease efﬁciently cleaves mouse MAVS and TRIF. (A)
pseudotyped TRIP-NS3/4A (JFH1)-puro2atagRFP and sorted for high expression of the v
(blue) Huh7.5 cells stained for HCV NS5A 72 hours following infection. (B) Western blo
mouse and human MAVS, TRIF and β-actin. (C) Selection of SGR-bsd-JFH1-containing colo
showing colonies of crystal violet stained cells. (D) Quantitation of crystal violet-positi
detecting mouse and human MAVS in either control or replicon-containing Huh7.5 cellproteolytic cleavage by the NS3/4A protease. In murine cells, the
NS3/4A protease cleavage motifs of mouse MAVS and TRIF are
conserved, but it has not been formally proven that the viral
protease actually cleaves the murine ortholog and that this
targeted proteolysis translates into increased RNA replication.
Thus, it is conceivable that different kinetics and/or a greater
magnitude of virally induced innate defenses prevent induction or
maintenance of HCV RNA replication in mouse cells. This hypoth-
esis is supported by the previous observation that mouse embryo-
nic ﬁbroblasts (MEFs) with targeted disruptions protein kinase R
(PKR; (Chang et al., 2006)) or interferon regulatory factor 3 (IRF3;
Lin et al., 2010b) are more conducive to HCV RNA replication. In
contrast, infectious HCV particles can assemble and be released in
mouse cell lines if apolipoprotein E is sufﬁciently expressed (Long
et al., 2011b) suggesting that later stages in the HCV life cycle are
not blocked in mouse cells.
In this study we attempted to recapitulate the entire HCV life-
cycle in mouse cells. Speciﬁcally, we demonstrate that the HCV
NS3/4A serine protease is capable of cleaving MAVS and TRIF in
mouse cells, thereby creating an environment which more efﬁ-
ciently supports HCV RNA replication. However, this evasion
mechanism is not sufﬁcient to readily overcome host defenses
interfering with HCV RNA replication in mouse cells. MEFs derived
from mouse strains harboring targeted deletions in genes critically
involved in type I and III interferon signaling can improve the
efﬁciency of HCV RNA replication, especially in the presence of the
liver-speciﬁc microRNA 122 (miR122), a host factor that was
previously shown to be important for HCV RNA replication
(Jopling et al., 2005). In accordance with a previous study (Long
et al., 2011a; Scull and Ploss, 2012), expression of human or mouse
apoE in mouse ﬁbroblasts infected with a selectable infectious
HCV genome with apoE results in production of infectiousmMAVS 53kD
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A. Vogt et al. / Virology 444 (2013) 1–11 3particles. Taken together, these data show that all steps of the HCV
life cycle can be recapitulated in murine cells, providing the
framework for an inbred mouse model of HCV infection.IRF 1 -/-
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Fig. 2. Innate immune deﬁciencies and expression of miR122 facilitate replication
of HCV replicons in mouse ﬁbroblasts. Immortalized MEFs (iMEFs) of the indicated
genotypes were lentivirally transduced with GFP or miR122 and then transfected
with replication-competent (wild-type) or defective (GNN) bicistronic subgenomic
(JFH1) constructs expressing blasticidin S deaminase (bsd) gene that confers
resistance blasticidin selection. Cells were selected in blasticidin-containing med-
ium and stained with crystal violet after ﬁxation.Results
Cleavage of MAVS and TRIF improves HCV RNA replication
in mouse cells
To test whether the NS3/4A serine protease is capable of
cleaving mouse MAVS and TRIF, two of the known targets of
NS3/4A in human cells, we transduced H2.35 mouse hepatoma
cells with a lentivirus TRIP-NS3/4A-TagRFPpuro expressing an
enzymatically active HCV NS3/4A (JFH-1) with a TagRFP-
puromycin fusion protein expressed in a downstream cistron. This
allowed us to sort ﬂowcytometrically a mouse cell population
expressing similar levels of NS3/4A to human Huh7.5 cells infected
with the robustly replicating J6/JFH1 clone 2 virus (Walters et al.,
2009) (Fig. 1A and B). In the parental H2.35 and Huh7.5 cells MAVS
and TRIF can be detected using speciﬁc antibodies for the respec-
tive proteins. In mouse cells overexpressing NS3/4A and Huh7.5
cells infected with HCV, the proteolytic products of mouse and
human MAVS and TRIF were readily detectable (Fig. 1B), suggest-
ing that HCV NS3/4A protease mediated immune evasion occurs in
mouse cells.
To assess whether NS3/4A-mediated cleavage of mouse MAVS
and TRIF would render mouse cells more permissive to HCV RNA
replication, we transfected H2.35 cells with TRIP-NS3/4A-TagRFP-
puro and selected for cells highly expressing the HCV protease. We
then transfected NS3/4A-expressing cells and H2.35 controls with
a selectable subgenomic JFH1 replicon (SGR-bsd-JFH1) encoding
the blasticidin resistance gene blasticidin-S-deaminase (bsd).
When selected with blasticidin, H2.35 cells expressing NS3/4A
formed 8–10 times more colonies (Fig. 1C and D) than NS3/4A-
negative controls, suggesting that NS3/4A expression signiﬁcantly
blunted innate antiviral signaling in mouse hepatoma cells,
thereby boosting HCV replication.
Blunting antiviral innate defenses improves HCV RNA replication
in mouse cells
HCV can replicate in mouse cells lines suggesting that murine
orthologs of host factors critical for HCV replication cooperate
sufﬁciently with the virally encoded replication machinery. HCV
replication is augmented in mouse cells lacking expression of the
protein kinase R (Chang et al., 2006) or interferon regulatory factor
3 (IRF3) (Lin et al., 2010b), HCV replication is augmented suggest-
ing that antiviral immunity limits viral replication in mouse cells.
Our data above indicate HCVs antiviral evasion mechanisms are
functional, but not readily capable of overcoming innate cellular
defenses. To identify a murine environment that is more conducive
for robust HCV replication we surveyed a larger panel of MEFs
deﬁcient in genes critically involved in type I and III interferon
responses, including PKR (Balachandran et al., 1998), RIG-I (Kato
et al., 2005), IRF-1 (Kimura et al., 1994; Matsuyama et al., 1993),
IRF-3 (Sato et al., 2000), IRF-7 (Honda et al., 2005), IRF-9 (Kimura
et al., 1996), STAT1 (Durbin et al., 1996), IFNαβ receptor (Muller
et al., 1994) or a knock-in strain with a dead mutation in the
helicase of LGP2 (Satoh et al., 2010) for their ability to replicate
HCV RNA. We generated immortalized MEFs (iMEFs) from these
strains as they provide a clean knock-out background for the gene
of interest. Liver-speciﬁc micro-RNA 122 (miR122) is a critical host
factor regulating HCV RNA translation and replication (Henke
et al., 2008; Jopling et al., 2005). It has previously been demon-
strated that exogenous administration of miR122 can boostHCV RNA replication in non-hepatic human (Da Costa et al., 2012b)
and murine cells (Lin et al., 2010a). In order to more closely mimic
the murine hepatic environment, we transduced iMEF lines from
the various innate immune knockout backgrounds with a lenti-
virus expressing miR122. This resulted in stable expression of
miR122 to similar levels detectable in highly permissive Huh7.5
cells (data not shown). iMEFs expressing miR122 or control cells
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Fig. 3. Persistent HCV RNA replication in mouse ﬁbroblasts on immunodeﬁcient backgrounds. Immortalized MEFs of the indicated genotypes or Huh7.5 cells were
transfected with full-length J6/JFH1 (FLR) or subgenomic JFH1 replicons expressing blasticidin S deaminase and cell populations selected in the presence of blasticidin.
(A) Quantiﬁcation of HCV NS5A antigen positive cells over six passages following HCV RNA transfection. (B) Representative ﬂow cytometry plots of IFNαβR-/- and Huh7.5 cells
stably harboring FLR- or SGR-stained for HCV NS5A antigen. C. Quantiﬁcation of HCV RNA over several passages in Huh7.5 and STAT1-/- iMEFs stably replicating SGRs or FLRs
as indicated. D. STAT1-/- iMEFs stably replicating SGRs or FLRs were grown in the presence or absence of 2′CMA (2mM) and stained with crystal violet after ﬁxation.
LOQ¼ limit of quantitation.
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A. Vogt et al. / Virology 444 (2013) 1–11 5were transfected with SGR-bsd-JFH1 and drug selection was
applied. Transfection of the SGR-bsd-JFH1 replicons into iMEFs
derived from wild-type control mice resulted in negligible num-
bers of blasicidin resistant cells irrespective of the presence of
miR122 (Fig. 2). In contrast, in the absence of RIG-I, IRF-3, IRF-9,
IFNαβR, STAT1 but not IRF-1 or IRF-7 SGR-bsd-JFH1 conferred
resistance to blasticidin selection, indicating that blunting speciﬁc
antiviral signaling pathways improves HCV RNA replication. iMEF
lines stably replicating HCV RNA expressed HCV NS3 which
correlated with efﬁcient cleavage of mouse MAVS (Fig. 1E). In
order to provide additional evidence for HCV RNA replication we
quantiﬁed HCV NS5A-positive cells by ﬂow-cytometry over multi-
ple passages in iMEF replicon lines harboring SGR-bsd-JFH1 and
maintained under bsd selection (Fig. 3). HCV NS5A protein was
detectable in iMEFs lacking RIG-I, IRF-3, IRF-9, IFNαβR and STAT1
harboring either subgenomic JFH1 or full-length (FL) J6-JFH1
replicons (Fig. 3A and B; and data not shown). The frequency of
NS5A positive cells was expectedly lower in the iMEFs lines
harboring SGR-bsd-JFH1 compared to Huh7.5 cells replicating
either full-length (FL) or subgenomic replicon-based (SGR) HCV
genomes. However, HCV RNA was readily detectable in STAT1-/-
and IFNαβR-/- iMEFs (data not shown) harboring SGR or FL
replicons at levels comparable to or only slightly lower than
replicon-containing Huh7.5 cells (Fig. 3C). When treated with 2′C
methyl adenosine (2′CMA), an inhibitor of the HCV NS5B poly-
merase, STAT1-/- iMEFs that previously stably replicated SGR or FLhOCLN
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transduced with miR122 and HCV entry factors, untreated iMEFs and Huh7.5 cells.genomes did not withstood blasticidin selection, pointing to
robust HCV replication on the STAT1-/- background. For all sub-
sequent experiments we primarily used STAT1-/- iMEFs because of
their superior stable growth under bsd selection when harboring
replicating HCV RNA. Taken together, these data demonstrate that
HCV replicates efﬁciently in non-hepatic mouse cell lines with
disrupted type I/III IFN signaling pathways.
Initiation of HCV life-cycle following infection of mouse cells
expressing human CD81 and OCLN with HCVcc.
Transfection is likely to introduce considerably more HCV RNA
into a cell as compared to a natural infection process. Thus, HCV
virion uptake via receptor-mediated endocytosis may prevent
putative hyperactivation of antiviral signaling pathways. It was
previously demonstrated that CD81, SCARB1, CLDN1 and OCLN are
required for HCV entry into rodent cells and CD81 and OCLN
constitute the minimal set of human genes required for viral
uptake in vitro and in vivo (Dorner et al., 2011; Ploss et al., 2009).
To determine whether the HCV life-cycle could be established in
iMEFs defective in STAT1, we transduced these cells with human
ﬂuorescently-tagged CD81, SCARB1, CLDN1 and OCLN and subse-
quently with miR122 (Fig. 4A). Expression of human entry factors
was conﬁrmed by ﬂow cytometry 3 days following transduction.
Approximately 30% of all cells expressed both human CD81 and
OCLN and a subset of those also expressed human CLDN1 andStaining with crystal violet
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with Jc1-5AB bsd or non-infected control cells. (D) Flow cytometry quantiﬁcation of
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s. (G) miR122 expression in Jc1-5AB bsd infected or non-infected STAT1-/- iMEFs
A. Vogt et al. / Virology 444 (2013) 1–116SCARB1 (Fig. 4E middle panels). Similarly, lentiviral delivery of
miR122 resulted in robust expression of the microRNA reaching
levels equivalent to those in highly permissive Huh7.5 cells
(Fig. 4G). To visualize HCV infection more readily we constructed
a recombinant HCV genome expressing bsd between NS5A and
NS5B, Jc1-5AB bsd (Fig. 5A and (Horwitz et al., 2013)). Jc1-5AB bsd
replicates following electroporation in Huh7.5 cells (Fig. 5B),
produces infectious particles (Fig. 5C), both albeit lower than the
parental Jc1 genome and renders cells replicating the genome
resistant to blasticidin selection (Fig. 5D and E).
Following infection of human entry factor- and miR122-
transduced STAT1-/- iMEFs with a control virus or Jc1-5AB bsd
and application of selection pressure, only cells that expressed
HCV entry factors and miR122 and were infected with Jc1-5AB bsdmock
Jc1
Jc1 5AB bsd
MOI = 0.1 MO
jc1 5jc1mock
Fig. 5. Construction of selectable HCVcc by insertion of bsd between NS5A and NS5B. (A
gene (bsd) by duplicating the NS3/4A protease cleavage site between NS5A and NS5B (NS
in vitro-transcribed RNA of Jc1 or Jc1-5AB bsd into Huh7.5 cells as measured by ﬂow cyto
following electroporation of Jc1 and Js1-5AB bsd RNA into Huh7.5 cells. (D) Schematic de
(E) Huh7.5 cells infected with Jc1 (MOI¼0.1), Jc1-5AB bsd (MOIs¼0.1 or 1), selected wiwere resistant to the antibiotic (Fig. 4B). Further analysis of the
cells that, stably replicated Jc1-5AB bsd revealed that the majority
of cells (460%) expressed high levels of HCV NS5A antigen—
evidenced by immune-histochemical staining (Fig. 4C) and ﬂow-
cytometric quantitation (Fig. 4D). Notably, following bsd selection,
expression of HCV entry factors was skewed towards substantially
higher expression, in particular human CD81 and human OCLN
(485% cells) suggesting a beneﬁcial effect presumably due to de
novo infection and spread within the culture (Fig. 4E, bottom
panels). Indeed, the NS5A staining intensity correlated with the
frequency of human CD81/OCLN double positive cells (Fig. 4F).
These data demonstrate that HCV replication can be initiated and
maintained in murine cells expressing HCV entry factors following
uptake of infectious HCV.bsd
MOI = 1I = 0.1
AB bsd jc1 5AB bsd
) Genome structure of Jc1-5AB bsd illustrating the insertion a blasticidin resistance
5A/B CS) ﬂanking the bsd insertion. (B) HCV replication following electroporation of
metry. (C) Longitudinal virus production as measured by end-point limiting dilution
piction of the experimental set-up for the selection of blasticidin resistant colonies.
th bsd and stained with crystal violet following ﬁxation.
A. Vogt et al. / Virology 444 (2013) 1–11 7Production of infectious virions in mouse cell lines.
It was recently demonstrated that mouse hepatoma cells stably
harboring a subgenomic HCV replicon can produce infectious
particles when transcomplemented with the missing HCV struc-
tural proteins (Long et al., 2011a). This further afﬁrms that virion
production is dependent on an intact VLDL pathway, in particular,
expression of apoE, irrespective of human or mouse species origin.
We aimed to determine whether mouse cells of non-hepatic origin
supplemented with mouse apoE are capable of supporting release
of infectious HCV virions. iMEFs lacking STAT1 or Huh7.5 cells
were transduced with HCV entry factors, miR122 and/or mouse
apoE, infected with Jc1-5AB bsd and subjected to bsd selection
(Fig. 6A). To determine whether the STAT1-/- iMEFs supplemented
with hCD81, hSCARB1, hCLDN1 and hOCLN, miR122 and/or mouse
apoE produced infectious particles, we passed cell culture super-
natants on naïve Huh7.5 cells. Only iMEFs expressing apoE
released infectious particles, albeit at low levels. These data
conﬁrm that mouse cells even of non-hepatic origin can produce
infectious HCV simply by overexpressing apoE (Long et al., 2011a).
We demonstrate for the ﬁrst time that this can be achieved with a
mono-cistronic HCV genome, which expresses the HCV geneiMEF Stat1 -/-
human entry factors (EF) 
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Fig. 6. Production of infectious HCV in mouse ﬁbroblasts supplemented with apoE.
(A) Schematic of the experimental set-up. (B) Infection of naïve Huh7.5 cells with
supernatants from cultures of STAT1-/- iMEFs transduced with mouse apoE, eGFP,
mock transduced iMEFs, and Huh7.5. NS5A staining was performed 72 h post
infection and the number of infectious virions quantiﬁed in a limiting dilution
assay. LOD¼ limit of detection.products presumably in stoichiometric ratios as opposed to mouse
cells harboring a subgenomic replicon in which structural proteins
are overexpressed.Discussion
HCVs narrow host range, limited to humans and chimpanzees,
is incompletely understood. Given the NIH moratorium on ‘non-
essential’ chimpanzee research that will severely limit future
chimpanzee HCV research, alternative animal models are urgently
needed to study HCV associated pathogenesis and to aid HCV
vaccine development. Different approaches have been taken to
construct small animal models for HCV infection (reviewed in
(Ploss and Rice, 2009)): efforts have been made to adapt HCV to
infect cells of non-human origin. Alternatively, the murine host
can be engineered to provide an environment that is conducive to
HCV infection. One approach requires humanization of relevant
human tissue compartments, in particular the liver and immune
system, via xenotransplantation resulting in so called ‘humanized
mice.’ Human liver chimeric mice, in particular, have proven useful
to study HCV and to test anti-viral regimens (reviewed in
Meuleman and Leroux-Roels (2008)). However, generation of
xenotransplanted mice requires a high degree of technical skills,
is costly and low in throughput, which limits their practical use. In
an effort to more systematically deﬁne host determinants required
to overcome species barriers we have identiﬁed the combination
of human CD81 and OCLN as the minimal set human cellular
factors required to facilitate entry into rodent cells (Ploss et al.,
2009). Capitalizing on this discovery we subsequently translated
these in vitro observations to a mouse model supporting viral
uptake (Dorner et al., 2011, 2012). While this alternative host
adaptation approach demonstrates how barriers of interspecies
transmission can be overcome genetically, this particular huma-
nized mouse model can only be used to monitor early steps in the
viral life-cycle in vivo as it does not support HCV replication and
virion assembly. These data are consistent with previous observa-
tions demonstrating that HCV RNA cannot readily replicate in
mouse hepatocytes in vivo (McCaffrey et al., 2002). However,
dominant-negative restriction factors do not seem to be present
in mouse cells as HCV is generally capable, albeit at low levels,
to replicate in murine hepatoma cells (Frentzen et al., 2011;
Zhu et al., 2003).
Here, we attempted to shed light on restrictions of HCV species
tropism in cells derived from non-permissive species. Our data
demonstrate that species barriers can be overcome by engineering
a suitable cellular environment. It was previously shown that the
virally encoded NS3/4A protease is not only critical for processing
of the HCV polyprotein but also cleaves numerous cellular targets
(reviewed in Morikawa et al. (2011)). In particular, cleavage of the
antiviral signal mediators MAVS and TRIF has been inferred as one
way HCV interferes with innate immune responses. Here, we
formally demonstrate that the NS3/4A protease does indeed
degrade the murine orthologs of both MAVS and TRIF. Conse-
quently, this cleavage moderately increases the ability of HCV to
replicate in mouse cell lines. However, this antiviral evasion
strategy does not seem to be sufﬁcient for HCV to readily establish
persistent RNA replication. In order to interrogate whether more
severe interference with antiviral signaling would boost viral
replication we surveyed cell lines derived from a number of mouse
knock-out lines. In contrast to a knock-down approach which fails
to completely abrogate gene expression and can have considerable
off-target effects (Buehler et al., 2012; Marine et al., 2012),
targeted disruptions of genes provides a clean null background
for the allele of interest. We demonstrate that mouse embryonic
ﬁbroblast lines derived from mice impaired type I and/or III
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data are consistent with previous observations showing that HCV
can replicate more efﬁciently in PKR and IRF3 deﬁcient ﬁbroblasts
(Chang et al., 2006; Lin et al., 2010b).
Besides interfering with innate responses it is conceivable that
incompatible host factors modulate HCV RNA replication in mouse
cells. It was demonstrated initially in cell culture that the liver
speciﬁc miRNA122 plays an important role in the HCV life-cycle
(Jopling et al., 2005) which was later corroborated in vivo (Lanford
et al., 2010). Two sites in the HCV 5′ non-translated region appear
to interact with miR122 (Jopling et al., 2008, 2005). These inter-
actions were shown to be critical for efﬁcient HCV RNA replication,
presumably by protecting 5′ terminal viral sequences from nucleo-
lytic degradation or from inducing innate immune responses to
the RNA terminus (Machlin et al., 2011), resulting in greater viral
RNA abundance in both infected cultured cells and in the liver of
infected chimpanzees (Lanford et al., 2010). Not surprisingly,
ectopic expression of the liver speciﬁc microRNA 122 in MEFs
slightly augments HCV RNA replication, which is supported by
results from previous studies (Lin et al., 2010b). However, this
pronounced effect of miRNA122 overexpression is more likely a
reﬂection of the non-hepatic cellular background used here than a
bona-ﬁde species restriction factor. In fact, the exact sequence of
miR122 is highly conserved in vertebrate species; comparatively,
mouse miR122 is identical in sequence and with 50,000 copies per
hepatocytes, similar in expressed level to human miR122 (Chang
et al., 2004). Consequently, miR122 is not likely to contribute to
the restricted host tropism in non-permissive species. Interest-
ingly, HCV RNA replication in PKR deﬁcient iMEFs appeared to be
more dependent on the presence of miR122. It is conceivable that
in PKR deﬁcient cells, which are presumably less impaired in their
ability to mount antiviral innate responses, residual antiviral
signaling triggers expression of an ISG proﬁle, which still interferes
with HCV RNA replication. In contrast, in cells with more severe
innate immune signaling impairments, such as IRF9-/-, IFNabbR-/-,
or STAT1-/-, early signals upstream innate immune response
cascade triggered by HCV RNA terminus are not ampliﬁed and
thus do not translate into induction of an antiviral program.
Likewise, the 5′UTR of HCV may also be less susceptible to
nucleolytic degradation. Numerous other host factors have been
implicated in the HCV replication cycle (reviewed in
Bartenschlager et al. (2010)). Of those, the most convincing
experimental evidence has been provided for the critical role of
cyclophilin A (CypA) and phosphatidylinositol 4 kinase IIIα
(PI4KIIIα) in the HCV life-cycle. However, limited compatibility
between the virally encoded replication machinery and these host
factors is not likely since the human and murine protein sequences
of CypA and PI4KIIIα are highly similar (98.2% and 98.6%, respec-
tively). Nonetheless, it has not been shown whether ectopic
expression of human CypA, PI4KIIIα or other host factors may
increase HCV RNA replication in mouse cells.
We demonstrate that expression of HCV entry factors in the
most permissive immunodeﬁcient cellular backgrounds allows for
initiation of replication via infection. Interestingly, we observe a
strong skewing towards high expression of human CD81, SCARB1,
CLDN1 and OCLN. High-level expression of HCV entry factors may
be beneﬁcial for efﬁcient spread in the cell culture. Given the fact
that we were only able to measure detectable levels of infectious
particles when apoE was expressed infection of neighboring cells
may via a direct cell-to-cell transfer in this culture system.
Consistent with previous data (Long et al., 2011a) we show that
expression of mouse apoE does support assembly of infectious
virions. While Long and colleagues used a transcomplementation
system (Long et al., 2011a) we show here that mouse cells can
assemble and release monocistronic recombinant viruses. It is
important to note that apoE, as part of the VLDL pathway, is highlyexpressed in the mouse liver. Thus, the need for overexpression of
apoE to complete the late stages of the HCV life-cycle in cell lines
as shown here and in other studies (Da Costa et al., 2012a; Long
et al., 2011a) highlights the artiﬁcial nature of commonly used cell
culture systems.
In summary, we deﬁne here the essential elements to recapi-
tulate the entire HCV life-cycle in murine cell lines. Experimental
evidence to validate these observations in vivo is underway.
Undoubtedly, additional improvements to the genetically huma-
nized mouse model would provide unprecedented opportunities
to genetically dissect HCV infection and pathogenesis in vivo and
will also serve as tractable, low-cost preclinical platform for
testing and prioritizing drug and vaccine candidates.Materials and methods
Cells and antiviral drugs
Mouse embryonic ﬁbroblasts (MEFs) were generated from day
12.5 or 13.5 embryos from Irf1tm1Mak (IRF1-/-)(Matsuyama et al.,
1993) (obtained from the Jackson Laboratory, Bar Harbor, Maine,
USA), Ifnar1tm1Agt (IFNαβR-/-) (Muller et al., 1994) (obtained from
B&K Universal Ltd (Hull, UK)) and Stat1tm1Dlv (STAT1-/-) (Durbin
et al., 1996) from Taconic (Hudson, NY, USA). Bcl2l12/Irf3tm1Ttg (IRF3-/-)
(Sato et al., 2000), Irf7tm1Ttg (IRF7-/-) (Honda et al., 2005) and Irf9tm1Ttg
(IRF9-/-) (Kimura et al., 1996) (kindly provided by Tadatsugo Taniguchi,
University of Tokyo, Tokyo, Japan), Dhx58tm1(A30K)Aki (LGP2K30A/K30A)
(Satoh et al., 2010) (kindly provided by Takashi Satoh and Shizuo Akira,
Osaka University, Osaka, Japan), Eif2ak2tm1Cwe (PKR-/-) (Yang et al.,
1995) (kindly provided by Adolfo Garcia-Sastre (Mount Sinai
School of Medicine, New York, NY, USA) immortalized via trans-
duction with TRIP-SV40 large T antigen. RIG-I MEFs originating
from the Akira lab were made available through Alexander
Tarakhovsky (The Rockefeller University). Huh 7.5 cells, Huh 7.5.1
cells, immortalized MEFs (iMEFs), 293 T cells, and H2.35 cells were
cultured in DMEM with 10% fetal bovine serum (FBS) and peni-
cillin/streptomycin, if not noted otherwise. Media were supple-
mented with blasticidin, puromycin and 2′C methyl adenosine
(2′CMA) as indicated. 2′CMA was the gift of. D. Olsen and S. Carroll
(Merck Research Laboratories, West Point, PA) and also was
obtained from Carbosynth Limited.
Generation of recombinant HCV plasmids
HCV replicons
The full length replicon contains the J6/JFH-1 polyprotein
expressed from an encephalomyocarditis virus internal ribosomal
entry site (EMCV-IRES). In an upstream cistron, the HCV 5′
untranslated region (UTR) drives expression of the ﬁrst 19 amino
acids of J6 core followed by blasticidin S-deaminase (bsd) contain-
ing a C-terminal STOP codon. Transfected into permissive cells, a
blasticidin resistant population can be selected and infectious
virus produced. The replication-impaired full-length construct
contains two mutations in NS5B (GDD-GNN) that render this
virus incapable of replication by deactivation of the viral poly-
merase. Transfected into permissive cells this replicon will be
translated but no replication will take place. The other replicon
used contains the subgenomic JFH-1 polyprotein including the
nonstructural protein set (NS3-NS5B) expressed from an EMCV
IRES. In an upstream cistron, the HCV 5′UTR drives expression of
the ﬁrst 19 amino acids of J6 core followed by blasticidin
S-deaminase (bsd) containing a C-terminal STOP codon. Trans-
fected into permissive cells, a blasticidin resistant population can
be selected, but no infectious virus is released from the cells.
Comparable to the full length a replication impaired subgenomic
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construct incapable of replication by deactivation of the viral
polymerase. After initial translation no replication of the viral
genome occurs.
Infectious viruses
HCVcc containing bsd between NS5A and NS5B: A detailed
characterization of the HCV expressing heterologous proteins
ﬂanked by NS3/4A cleavage sites within the HCV polyprotein is
described elsewhere (Horwitz et al., 2013). Brieﬂy, we generated a
Gateways-compatible destination vector (Invitrogen, Life Tech-
nologies, Carlsbad, CA) based upon the fully infectious Jc1 HCV
genome, Jc1-5AB-DEST, for insertion of reporter genes between
NS5A and NS5B. The 9-amino acid region spanning P7-P2′ of the
NS3/4A proteolytic cleavage site between NS5A and NS5B was
positioned on both ends of the destination cassette. Jc1-5AB-DEST
was generated by PCR ampliﬁcation of the Gateways (Invitrogen,
Life Technologies, Carlsbad, CA) destination cassette and insertion
into the DraIII restriction site at the 3′ end of Jc1(2a) NS5A using
standard molecular cloning techniques. Jc1-5AB-BSD was gener-
ated by PCR ampliﬁcation of blasticidin S deaminase (bsd) with
primers containing AttB sites for Gateways-mediated insertion
into pDONR™221, and subsequent BP and LR reactions were
performed.
Jc1FLAG2(p7-nsGluc2A) is a fully-infectious HCVcc virus that
has been previously described (Marukian et al., 2008;
Pietschmann et al., 2006). J6/JFH Clone2 is a passaged derivative
of J6/JFH that contains a number of adaptive mutations that
increase infectious titers (Walters et al., 2009).
RNA transcription.
In vitro transcripts were generated as previously described
(Lindenbach et al., 2005). Brieﬂy, plasmid DNA was linearized by
XbaI and puriﬁed by using a Minelute column (Qiagen, Valencia,
CA). RNA was transcribed from 1 μg of puriﬁed template by using
the T7 Megascript kit (Ambion, Austin, TX) or the T7 RNA
polymerase kit (Promega, Madison, WI). Reaction mixtures were
incubated at 37 1C for 3 h, followed by a 15-min digestion with 3 U
of DNase I (Ambion, Austin, TX). RNA was puriﬁed by using a
RNeasy Mini kit (Qiagen) with an additional on-column DNase
treatment. RNA was quantiﬁed by absorbance at 260 nm and
diluted to 0.5 μg/μl. Prior to storage at −80 1C, RNA integrity was
determined by agarose gel electrophoresis and visualization by
ethidium bromide staining.
HCVcc generation
Jc1 NS5AB bsd and Jc1FLAG(p7ns Gluc2A) were generated by
electroporating in vitro transcribed RNA into Huh7.5.1 cells. After
72 h the medium was changed from 5% FBS to 1.5% FBS. The
supernatants were collected every 6 h from 72 to 144 h after
transfection and concentrated through a 100 kDa MWCO mem-
brane using a Stirred Ultraﬁltration Cell. Supernatant from J6/JFH1
clone 2 electroporated Huh7.5.1 cells was collected daily from 72
to 144 h but not concentrated. The virus infectivity was deter-
mined by limiting dilution as described previously (Lindenbach
et al., 2005).
Pseudoparticles
Construction of proviral constructs
TRIP-HCV(JFH1)–NS3/4A-TagRFP/Puro. This TRIP-based bicistronic
lentiviral vector encodes the HCV NS3/4A protease as a single-chain
fusion protein driven by a CMV promoter. The downstream cistronis driven by an encephalomyocarditis virus internal ribosomal
entry site (EMCV-IRES) and encodes a fusion protein containing a
puromycin resistance gene followed by a foot and mouth disease
virus autoproteolytic peptide and TagRFP (Puro-2A-TagRFP).
Transduction of permissive cell lines with these pseudoparticles
results in stable expression of functional NS3/4a and Puro-2A-
TagRFP. Transduced cell populations were selected on puromycin,
and sorted using ﬂuorescence based life cell sort.
TRIP-mApoE-TagRFP. The cDNA clone of murine apolipoprotein E
was obtained in pCMV6 (Origene NM_009696). mApoE was PCR
ampliﬁed from the cDNA vector and ﬂanking attB sites added
using primers RU-O-16597 and RU-O-16596, allowing us to insert
the resulting product into pDONOR221 (Invitrogen, containing attP
sites) using BP clonase II and Gateway cloning technology. mApoE
was then shuttled into the destination vector pTRIP.CMV.IVSb.ires.
TagRFP-DEST (Schoggins et al., 2011) using LR clonase II (Gateway
cloning technology, Life Technologies).
TRIP-miRNA122. The proviral plasmid was generated by insertion
of the miR122-generating hairpin-loop structure from pCMV-
miR122 into the BamHI/XhoI digested pTRIP-GFP.
HCV entry factors. Generation of TRIP-human CD81(Flint et al.,
2006), -Venus/YFP-human OCLN and -human OCLN(Ploss et al.,
2009), -Cerulean/CFP-human CLDN1 (Ploss et al., 2009), human
CLDN1(Evans et al., 2007) and human SCARB1 (Catanese et al.,
2010) were described previously. TRIP-mKate-human SCARB1 was
generated by overlapping PCR of the coding sequence of mKate,
also designated as TagFP635(Shcherbo et al., 2007) (Evrogen) and
human SCARB1 resulting into an N-terminal fusion protein which
was subsequently cloned into the BamHI/XhoI digested pTRIP-GFP.
Pseudoparticle generation
All pseudoparticles were generated as described previously
(Ploss et al., 2009) in 293 T cells by FuGENE6 (Roche Applied
Science, Indianapolis)-mediated cotransfection of plasmids encod-
ing (1) a minimal HIV provirus (TRIP) encoding a reporter gene
or other transgene, (2) HIV gag-pol and (3) and VSV-G.
Pseudoparticle-containing supernatants were harvested at 24, 48
and 72 h were pooled and ﬁltered (0.45 μm mesh). Pseudoparticle
infections were performed in the presence of 4 μg /ml polybrene. A
minimum of 48 h elapsed between transduction and reporter gene
quantiﬁcation or subsequent experiments.
Transfection of HCV RNA into mouse and Human cell lines
For all replicon experiments cells were plated in tissue culture
treated 6 well (210E5 cells) or 10 cm (110E6 cells) plates one
day or in case of transduction with miRNA122 two days before the
transfection. In the latter case, the miR122 or GFP pseudoparticles
were applied on the day between seeding and transfection. Mirus
TransIT transfection kit was used to transfect 0.5 μg (6-well plate)
or 3 μg (10 cm dish) HCV replicon RNA into the cells. According to
manufacturer's instructions the transfection medium was changed
after six hours. We changed the medium to blasticidin containing
selection medium the day after transfection and from there on
regularly every 3 days. For all transfection experiments a concen-
tration of 1 μg/ml blasticidin was used for ca. 2 weeks before
raising the concentration to 2 μg/ml blasticidin for another two
weeks. After completing this month the plates were either ﬁxed in
PFA and stained using crystal violet or resistant cells were
trypsinized and passaged for further experiments. Only the
H2.35 cells were immediately exposed to 2 μg/ml blasticidin and
stained with crystal violet after 2 weeks.
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Transduced and control MEFs or Huh7.5 cells were infected
with HCVcc (J6/JFH1 clone 2), Jc1 NS-5AB bsd or Jc1FLAG2
(p7nsGluc2A as indicated)-containing supernatants one day after
cell seeding. For selection experiments, media was replaced the
next day and switched to medium containing blasticidin, increas-
ing the bsd concentration every 2 weeks from 1, to 2 to a ﬁnal
concentration of 6 μg/ml. Stably infected cells were either ﬁxed in
PFA and stained with crystal violet or resistant cells were passaged
for further experiments. To quantify HCV infection, cells were ﬁxed
in paraformaldehyde, permeabilized with saponin and stained for
NS5A with an Alexa488-conjugated 9E10 anti-NS5A antibody
(Lindenbach et al., 2005); the signal was quantiﬁed by ﬂow-
cytometrical analysis.
Flow cytometry
Expression of lentivirally-delivered transgenes was quantiﬁed
by ﬂow cytometry. CD81 expression was detected by staining with
an anti-human CD81-APC (clone JS81, Pharmingen), other proteins
were directly ﬂuorescently tagged, i.e. SCARB1 (mKate), CLDN1
(Cerulean) and OCLN (Venus), ApoE, NS3/4A (both TagRFP).
All samples were acquired on a LSR2 ﬂow cytometer (Becton
Dickinson, Franklin Lakes, NJ).
Western blotting
Cells (Huh7.5, H2.35 and indicated iMEF lines) were trypsinized
and the pellet was lysed using the following buffer: TRIS Base 1 M,
NaCl, Triton-X 20% and Mini EDTA-free protease Inhibitor (Roche).
After protein quantiﬁcation using a Pierce BCA Protein Assay Kit
(Thermo Scientiﬁc), equal amounts of protein were loaded onto
4–12% or 10% Bis/Tris NuPage polyacrylamide gels (Invitrogen).
Proteins were transferred to a nitrocellulose membrane and
detected with the respective antibodies: NS3 (Virostat #1878)
1:100, mMAVS (Cell Signaling #4983) 1:1000, hMAVS (Enzo #ALX-
804-847) 1:1000, TRIF (Novus #NB120-13810) 1:1000. β-actin was
detected as a loading control (Sigma #A3854) 1:200000. After
incubation with the respective secondary antibody the proteins
were visualized using Super Signal West Pico or Femto (Thermo
Scientiﬁc).
HCV RNA quantiﬁcation
After trypsinization, the total RNA from cell pellets was isolated
using the RNeasy Mini kit (Qiagen) and the HCV genome copy
number was quantiﬁed by one-step rtPCR using Multicode-RTx
HCV RNA kit (EraGen) and a Roche LC480 light cycler, according to
manufacturer's instructions.Authorship
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